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Summary  Targeting  epidermal  growth  factor  receptor  (EGFR)  is  an  important
treatment  option  for  non-small  cell  lung  cancer  (NSCLC).
These  targeted  therapies  have  been  studied  extensively  in  NSCLC  in  ﬁrst  line
and  subsequent  lines,  including  maintenance  in  empiric  fashion  or  in  patients  with
tumors  harboring  the  EGFR  mutations.
In  this  manuscript,  we  will  review  in  details  the  evolutions  of  these  targeted
therapy  in  the  management  of  NSCLC.
©  2012  Published  by  Elsevier  Limited  on  behalf  of  King  Saud  Bin  Abdulaziz  University
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Introduction
Lung  cancer,  the  leading  cause  of  cancer  death
world wide,  is  classiﬁed  histologically  to  small-cell
(15%)  or  non-small-cell  (85%).  Non-small-cell  lung
cancer (NSCLC)  is  further  divided  into  3  subtypes
based on  histology:  squamous-cell  carcinoma,  ade-
nocarcinoma,  and  large-cell  lung  cancer.As surgical  techniques  and  combination  treat-
ment regimens  have  improved,  the  1-year  survival
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ate  in  lung  cancer  has  increased  slightly,  from  35%
n 1975—1979  to  41%  in  2000—2003.  Nonetheless,
he 5-year  survival  rate  for  all  stages  of  lung  cancer
ombined  remains  around  15%.
The majority  of  patients  with  NSCLC  are  candi-
ates for  systemic  treatment  with  chemotherapy,
ither as  therapy  for  advanced  disease  or  as
djuvant  or  neoadjuvant  treatment  with  local
herapy  (surgery  or  radiation  therapy)  utilized  in
arlier stages.  However,  chemotherapy  has  only
hown modest  improvement  in  the  outcome  of
SCLC [1].  Chemotherapy  normally  yields  30%
esponse,  4  months  PFS  and  median  survival  of  8—11
onths.
Therefore,  new  treatment  approaches  are
eeded. Targeting  the  epidermal  growth  factor
eceptor (EGFR)  and  vascular  endothelial  inhibitor
VGEF)  has  played  a  central  role  in  advancing  NSCLC
 King  Saud  Bin  Abdulaziz  University  for  Health  Sciences.  All  rights  reserved.
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ppidermal  growth  factor  receptor  inhibitors  role  in
esearch,  treatment,  and  patient  outcome  over  the
ast several  years  [2].
This  manuscript  focuses  on  the  role  of  EGFR  in
SCLC  and  current  clinical  data  on  agents  targeting
he EGFR  pathway,  and  recent  advances  in  using
GFR inhibitor  in  clinical  practice.
GFR role in carcinogenesis
he  human  genome  encodes  approximately  518
inases,  of  which  there  are  90  Tyrosine  kinases
TKs) and  43  tyrosine-like  kinases.  EGFR,  — a
70-kDa (1186  amino  acid)  membrane-bound  pro-
ein encoded  by  28  exons  spanning  nearly  190,000
ucleotides  on  chromosome  7p12,  is one  member
f the  TK  family,  which  belongs  to  a  subfamily  of
our closely  related  receptors:  HER-1/ErbB1,  HER-
/neu/ErbB2,  HER-3/ErbB3,  and  HER-4/ErbB4.
Structurally,  EGFR  receptor  is  composed  of  an
xtracellular  ligand  binding  domain,  a  transmem-
rane domain,  and  an  intracellular  domain.  Upon
inding to  ligands,  such  as  epidermal  growth  fac-
or (EGF),  the  receptors  undergo  conformational
hanges that  facilitate  intermolecular  autophos-
horylation which  activate  EGFR  pathways  which
re important  for  cell  survival,  and  the  mitogen-
ctivated protein  kinase  (MAPK)  pathway,  which
nduces  proliferation.  EGFR  regulates  important
umorigenic processes  that  include  proliferation,
poptosis, angiogenesis,  and  invasion  [3,4].
The epidermal  growth  factor  receptor  is  a tyro-
ine kinase  (TK)  receptor  of  the  ErbB  family  that  is
ommonly  altered  in  epithelial  tumors.  EGFR  was
hown to  be  an  oncogene,  capable  of  inducing  can-
er when  aberrant.  So  using  speciﬁc  monoclonal
ntibodies against  the  EGFR  could  inhibit  its  activ-
ty. Since  EGFR  appeared  to  play  a  central  role  in
umorigenesis,  this  observation  implied  that  target-
ng the  receptor  itself  might  be  an  effective  way  to
reat EGFR-expressing  cancers  [3,4].
The  ﬁrst  anti-EGFR  drugs  were  developed  in  the
980s.  Two  classes  of  EGFR  antagonists  have  been
uccessfully  tested  in  phase  3 trials  and  are  now  in
linical use:  anti-EGFR  monoclonal  antibodies  and
mall-molecule  EGFR  tyrosine  kinase  inhibitors.
Cetuximab  is  an  example  of  anti-EGFR  mono-
lonal antibodies.  It  binds  to  the  extracellular
omain of  EGFR  when  it  is  in  the  inactive  conﬁgu-
ation, competes  for  receptor  binding  by  occluding
he ligand-binding  region,  and  thereby  blocks
igand-induced EGFR  tyrosine  kinase  activation
3,4].
Other small-molecule  EGFR  tyrosine  kinase
nhibitors, such  as  erlotinib  and  geﬁtinib,  compete
t
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eversibly  with  ATP  to  bind  to  the  intracellular  cat-
lytic domain  of  EGFR  tyrosine  kinase  and,  thus,
nhibit  EGFR  autophosphorylation  and  downstream
ignaling [3,4].
Mutation  was  found  in  16—39%  of  NSCLC.  Muta-
ion of  EGFR  mostly  deletion  of  speciﬁc  exons
ncoding part  of  the  extracellular  domain  of  the
GFR molecule,  leading  to  constitutive  receptor
ctivation (ligand-independent),  impaired  receptor
own regulation,  activation  of  alternative  signaling
ascades,  and/or  abrogation  of  apoptotic  mecha-
isms.  Exon  19  deletion  and  the  point  mutation  of
858R constitute  about  90%  of  all  EGFR  mutation
5—11].
EGFR is  commonly  over  expressed  in  the  devel-
pment and  progression  of  lung  cancer  62%  of  all
umors, 89%  of  squamous  tumors,  41%  of  adenocar-
inomas,  and  80%  of  bronchioloalveolar  tumors.
The somatic  mutations  are  observed  with
ncreased frequency  in  women  and  in  nonsmok-
rs. As  identiﬁed  from  previous  trials  3,  nonsmoker,
sian, adenocarcinoma  and  female  gender  were
ssociated  independently  and  collectively  with
mproved  response  to  EGFR  TKIs  [5].
HER2  kinase  domain  mutations  (in-frame  inser-
ions in  Exon  20)  are  also  associated  with  female
ender,  nonsmoking  status,  and  Asian  background
n patients  with  adenocarcinoma;  however,  these
utations  are  associated  with  resistance  to  EGFR
KIs (but  sensitivity  to  HER2-targeted  therapy).
onversely, HER2  ampliﬁcation  predicts  increased
ensitivity  to  EGFR  TKIs,  and  increased  copy  number
f the  HER2  gene  is  associated  with  geﬁtinib  sensi-
ivity in  EGFR-positive  patients,  supporting  use  of
ER2 FISH  analysis  for  selection  of  patients  for  TKI
herapy (see  Table  1).
Increased  EGFR  gene  copy  number  as  determined
y ﬂuorescent  in  situ  hybridization  (FISH)  and  EGFR
rotein overexpression  measured  by  immunohisto-
hemistry (IHC)  were  recently  reported  to  correlate
ith  improved  response  and  survival  with  geﬁtinib
nd cetuximab  treatment.  Furthermore,  signiﬁ-
ant survival  beneﬁt  from  erlotinib  therapy  was
bserved  in  patients  with  wild-type  KRAS  [12—15].
GFR inhibitors use in lung cancer
anagement
nti-EGFR  monoclonal  antibodies  (mAbs)  bind  com-
etitively to  the  extracellular  domain  of  EGFR,
hereby  preventing  ligand  binding  and  interrupting
he signaling  cascade.  TKIs  bind  to  the  intracel-
ular domain  of  EGFR  and  inhibit  the  downstream
ffects of  EGFR  ligand  binding.  TKIs  are  not
S52  A.  Al  Olayan  et  al.
Table  1  Studies  of  EGFR  targeted  therapy  in  non-small  cell  lung  cancer.
Medication  Line  Treatment  Patient  No  Outcome  Reference
Geﬁtnib First  line  Gemcitabine,  Carboplatin  and
Geﬁtinib  versus  Gemcitabine  and
carboplatin
80  patients  Medium  over  all
survival  20.5
versus  14.1
Tham  et  al.  [22]
Carbopaltin  and  Paclitaxol  versus
Geﬁtnib
1217 IPASS  [24]
Second  or Geftnib  versus  Taxtere 210 7.6 Interest
Third  line  216  [34]
Erlotnib  Third  line  Erlotnib  versus  placebo  731  6.7  versus  4.7  BR  21  [36]
Cetuximab  First  line  Cetuximab  with
vinorelbine/cisplatin  versus
chemotherapy  alone
1125  11.3  versus  10.1  FLEX  [29]
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aspeciﬁc  for  EGFR,  so  for  these  agents  there  may
be cross-reactivity  between  EGFR  and  other  ErbB
family members,  including  HER2.  It  appears  that
both categories  of  drugs  also  have  antiangiogenic
activity, with  a  negative  inﬂuence  on  the  angiogenic
biochemical mediators  VEGF  and  factor  VIII  [16].
First line treatment
Geﬁtinib
Geﬁtinib  is  the  ﬁrst  molecularly  targeted  agent  to
be registered  for  advanced  NSCLC.  The  approval
was based  on  two  large  randomized  phase  II  studies,
the Iressa  Dose  Evaluation  in  Advanced  Lung  Cancer
(IDEAL)-1  and  -2  studies  [17,18].
In  ﬁrst  line  treatment  of  lung  cancer  two
randomized,  placebo-controlled,  phase  3  trials,
INTACT  (Iressa  NSCLC  Trial  Assessing  Combina-
tion Treatment)  1  and  2,  evaluated  the  potential
beneﬁt of  adding  geﬁtinib  to  chemotherapy
for ﬁrst-line  treatment.  INTACT  1  evaluated
gemcitabine/cisplatin  plus  placebo  or  geﬁtinib
250 mg/day  or  500  mg/day  in  1093  chemotherapy-
naive patients  with  advanced  NSCLC.  The  trial
found no  difference  in  over-all  survival  (OS),
time to  disease  progression  (TTP),  or  over-all
response rate  (ORR)  between  the  3  treatment
groups, and  no  signiﬁcant  unexpected  adverse
events (AEs)  were  observed.  INTACT  2 evaluated
paclitaxel/carboplatin  plus  placebo  or  geﬁtinib
250 mg/day  or  500  mg/day  in  1037  chemotherapy-
naive patients  with  advanced  NSCLC  and  also  found
no difference  between  treatment  groups  in  overall
survival  (OS),  time  to  progression  (TTP),  or  overall
response  rate  (ORR).  Dose-related  diarrhea  and  skin
rash were  observed  with  geﬁtinib,  but  there  were
no unexpected  AEs  [19—21].
g
a
a
wIn  another  study,  80  patients  with  advanced
on-small cell  lung  cancer  (NSCLC)  and
ever smokers  were  assigned  to  receive
emcitabine—carboplatin—geﬁtinib  (GCI)  as
rst-line therapy  and  compared  these  patients
ith a  historical  control  group  who  received
emcitabine—carboplatin  (GC)  alone.  The  response
ate for  patients  in  the  GCI  group  was  62.7%  (95%
onﬁdence  interval  [CI]:  48.08—75.87),  which  was
igher than  that  of  the  GC  group,  27.6%  (95%  CI:
2.73—47.24).
The GCI  group  showed  a  signiﬁcant  improvement
n progression-free  survival  compared  with  the  GC
roup (hazard  ratio  of  0.19,  95%  CI: 0.105—0.351,
 <  0.001).  The  median  overall  survival  for  the
atients  on  GCI  was  20.5  months  compared  14.1
onths  (p  <  0.05)  for  patients  on  GC.
The addition  of  geﬁtinib  to  ﬁrst-line  chemother-
py improved  progression-free  survival  and  overall
urvival  when  used  as  a ﬁrst-line  therapy  in  the
roup of  patients  who  never  smokers  with  advanced
SCLC [22].
A  phase  II,  open-label,  parallel-group  study  com-
ared geﬁtinib  with  vinorelbine  in  chemotherapy
aıve elderly  patients  with  advanced  (NSCLC).
atients were  randomly  assigned  to  geﬁtinib  (n  =  97)
r to  vinorelbine  (n  =  99).  Results  showed  hazard
atios (HR;  geﬁtinib  vs  vinorelbine)  were  1.19  (95%
I: 0.85—1.65)  for  PFS  and  0.98  (95%  CI:  0.66—1.47)
or OS.  Disease  control  rates  were  43.3%  for  geﬁti-
ib and  53.5%  for  vinorelbine,  ORR  3.1%  for  geﬁtinib
nd 5.1%  for  vinorelbine.  Overall  QOL  improvement
nd PSI  rates  were  24.3%  and  36.6%  (for  geﬁtinib)
nd 10.9%  and  31.0%  (for  vinorelbine),  respectively.
There was  no  statistical  difference  betweeneﬁtinib and  vinorelbine  in  efﬁcacy  in  chemother-
py naıve,  unselected  elderly  patients  with
dvanced NSCLC,  but  there  was  better  tolerability
ith geﬁtinib  [23].
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mpidermal  growth  factor  receptor  inhibitors  role  in
Iressa  Pan-Asia  Study  (IPASS)  trial  was  conducted
ecently as  a  phase  3,  randomly  assigned  previously
ntreated  patients  in  East  Asia  who  had  advanced
ung adenocarcinoma  and  who  were  nonsmokers  or
ormer light  smokers  to  receive  geﬁtinib  (250  mg
er day)  (609  patients)  or  carboplatin  plus  pali-
axel (608  patients).  The  primary  end  point  was
rogression-free  survival.  The  12-month  rates  of
rogression-free  survival  were  24.9%  with  geﬁtinib
nd 6.7%  with  carboplatin—paclitaxel.
In  the  subgroup  of  261  patients  who  were  pos-
tive for  the  epidermal  growth  factor  or  receptor
ene (EGFR)  mutation  (96%  have  Exon  19  dele-
ion or  Exon  21  L858R  mutation),  progression-free
urvival was  signiﬁcantly  longer  among  those  who
eceived  geﬁtinib  than  among  those  who  received
arboplatin—paclitaxel  (hazard  ratio  for  progres-
ion or  death,  0.48;  95%  CI:  0.36—0.64;  p  < 0.001),
hereas  in  the  subgroup  of  176  patients  who  were
egative  for  the  mutation,  progression-free  sur-
ival was  signiﬁcantly  longer  among  those  who
eceived  carboplatin—paclitaxel  (hazard  ratio  for
rogression  or  death  with  geﬁtinib,  2.85;  95%  CI:
.05—3.98;  p  <  0.001)  [24].
rlotinib
rlotinib  in  combination  with  chemotherapy  as  ﬁrst-
ine treatment  of  NSCLC  has  been  evaluated  in  two
arge multicenter,  randomized,  placebo-controlled
linical trials.
Two platinum-based  doublets  (carboplatin  plus
aclitaxel  or  cisplatin  plus  gemcitabine)  were  eval-
ated in  combination  with  erlotinib  versus  placebo
n the  Tarceva  Responses  in  Conjunction  with  Pacli-
axel and  Carboplatin  (TRIBUTE)  and  Tarceva  Lung
ancer Investigation  (TALENT)  trials,  respectively.
In the  TRIBUTE  study,  1000  patients  with
ntreated advanced  stage  IIIB/IV  NSCLC  were
nrolled. The  median  over-all  survival  time  (OS)  for
atients treated  with  erlotinib  was  10.6  months,
ersus 10.5  months  for  the  placebo  group,  the  over-
ll response  (OR)  rates  were  similar  in  the  erlotinib
nd placebo  arms  (21.5%  vs  19.3%,  respectively)
25].
In the  TALENT  trial,  likewise,  there  was  no  statis-
ically  signiﬁcant  difference  in  any  outcome,  with
 median  OS  of  301  versus  309  days,  respectively.
herefore,  there  was  no  clinical  beneﬁt  in  either
rial,  and  currently  concurrent  use  of  erlotinib  with
hemotherapy  is  not  recommended  in  the  ﬁrst-line
reatment  of  NSCLC  unless  the  tumor  has  EGFR
utation  [26].
Optimal  trial  was  phase  III  randomized  trial
onducted recently  in  China  assigned  previously
ntreated 154  patients  with  known  EGFR  mutations
c
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Exon  19  deletion  or  Exon  21  L858R  mutation)
nd measurable  disease  to  receive  erlotinib  or
emcitabine  plus  carboplatin.  Progression-free  sur-
ival was  signiﬁcantly  improved  with  erlotinib  (13.1
s 4.6  months,  HR  0.16,  95%  CI:  0.10—0.26).
imilarly, treatment  with  erlotinib  signiﬁcantly
mproved the  objective  response  rate  (83%  vs  36%)
27].
In the  EURTAC  trial,  174  chemonaive  patients
ith EGFR  mutation  (Exon  19  deletion  or  L858R
utation) were  randomly  assigned  to  erlotinib
r platinum-based  chemotherapy.  The  primary-
ndpoint was  progression-free  survival  which  was
igniﬁcantly  improved  with  erlotinib  (median  9.7  vs
.2 months,  HR  0.37).  The  difference  in  overall  sur-
ival was  not  statistically  signiﬁcant,  but  more  than
0% of  patients  initially  treated  with  chemother-
py subsequently  received  an  EGFR  tyrosine  kinase
nhibitor  [28].
etuximab
etuximab  is  an  IgG1 monoclonal  antibody  directed
gainst  the  extracellular  domain  of  the  EGFR,  which
uppresses  EGFR-mediated  cell  signaling  by  block-
ng ligand  binding  to  the  receptor.  As  an  IgG1
ntibody,  cetuximab  may  also  kill  tumor  cells  via
n immune  mechanism:  antibody-dependent  cel-
ular cytotoxicity.  Accordingly,  cetuximab  works
ifferently  from  the  TKIs.  Phase  III  clinical  trials
ave shown  that  cetuximab  prolongs  survival  in
atients with  metastatic  colorectal  cancer  (mCRC)
nd advanced  squamous  cell  carcinoma  of  the  head
nd neck.
In lung  cancer,  cetuximab  was  evaluated  in
rst line  setting.  Phase  II  study  of  patients  with
GFR positive  and  EGFR-negative  advanced  NSCLC
ith Eastern  Cooperative  Oncology  Group  perfor-
ance  status  0—1,  assigned  to  receive  cetuximab
00 mg/m2 intravenously  (IV)  on  week  1  followed
y weekly  doses  of  cetuximab  250  mg/m2 IV.  A
ycle was  considered  as  4  weeks  of  treatment  and
herapy  was  continued  until  disease  progression  or
ntolerable toxicities.
The  response  rate  for  all  patients  (n  =  66)  was
.5% (95%  CI:  0.9—12.7%)  and  the  stable  disease
ate was  30.3%  (95%  CI:  19.6—42.9%).  The  response
ate  for  patients  with  EGFR-positive  tumors  (n  =  60)
as 5%  (95%  CI:  1.0—13.9%).  The  median  time  to
rogression  for  all  patients  was  2.3  months  (95%  CI:
.1—2.6 months)  and  median  survival  time  was  8.9
onths (95%  CI:  6.2—12.6  months).
Although the  response  rate  with  single-agent
etuximab  in  this  heavily  pretreated  patient  pop-
lation with  advanced  NSCLC  was  only  4.5%,  the
isease control  rates  and  overall  survival  seem
a
d
E
g
r
e
w
a
f
m
d
r
S
o
t
5
i
[
E
d
p
w
b
t
t
p
i
s
r
o
0
s
R
p
h
e
g
p
E
m
t
r
l
l
a
N
aS54  
comparable  to  that  of  pemetrexed,  docetaxel,  and
erlotinib in  similar  groups  of  patients  [29].
The phase  3  FLEX  (ﬁrst-line  treatment  for
patients with  epidermal  growth  factor  inhibitor
[EGFR]-EXpressing  advanced  NSCLC)  trial,  of  cetux-
imab combined  with  vinorelbine/cisplatin,  met  its
primary endpoint  of  increasing  OS  when  compared
with chemotherapy  alone;  this  study  enrolled  1125
patients with  advanced  NSCLC  who  had  evidence  of
EGFR expression.
While  median  PFS  was  the  same  in  both  treat-
ment groups  (4.8  months),  median  OS  was  11.3
months  in  the  group  that  received  cetuximab  vs
10.1 months  in  the  group  that  received  chemother-
apy alone  (p  =  .044).  This  survival  time  was  viewed
unfavorably  due  to  failure  to  cross  the  newly  set
benchmark  of  12  months  achieved  by  other  targeted
therapy,  namely  bevacizumab  with  chemotherapy.
The 1-year  survival  rate  was  47%  in  the  cetuximab
group versus  42%  in  the  chemotherapy-alone  group.
The group  receiving  cetuximab  also  had  a signiﬁ-
cantly  better  response  rate  (36%  vs  29%,  p  =  .012).
Number  of  pre  speciﬁed  subgroup  analyses  for
potential  survival  beneﬁt  were  also  conducted.
While the  subgroup  of  white  patients  had  improved
OS with  cetuximab  (10.5  vs  9.1  months;  p  =  .003).
Asian patients  in  the  cetuximab  group  had  worse
survival  (17.6  vs  20.4  months),  suggesting  that
cetuximab  is  not  effective  in  this  subgroup  of
patients  (who  are  more  likely  to  harbor  EGFR  muta-
tions).  In  patients  with  squamous-cell  tumors,  OS
was numerically  better  with  cetuximab  (10.2  vs  8.9
months; p  =  .0567);  this  was  also  true  in  patients
with adenocarcinoma  (12.0  vs  10.3  months;
p =  .0673).  In  a  preplanned  analysis,  the  develop-
ment of  early  acne-like  rash  was  associated  with
signiﬁcant  outcome  (median  OS:  15  months  vs  8.8.
months, HR  0.63,  95%  CI:  0.52—0.77,  p  < 0.0001)
[29]. Data  from  FLEX  indicated  that  cetuximab  does
not appear  to  beneﬁt  patients  who  have  K-Ras
mutations. Unlike  colon  cancer,  K-Ras  testing  does
not help  identify  patients  who  are  most  likely  to
beneﬁt  from  treatment  with  cetuximab  [30].
Second and third line treatment
Geﬁtinib
In  IDEAL  1 study,  210  pretreated  patients  were  ran-
domized to  receive  geﬁtinib  at  250  or  500  mg/day.
The overall  RR  (ORR)  was  18.4%  and  19%  and  over-
all survival  (OS)  was  7.6  months  and  8.0  months  for
the lower  dose  and  the  higher  dose  groups,  respec-
tively.
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In  IDEAL  2 study,  216  patients  who  had  relapsed
fter platinum  and  docetaxel  regimens  were  ran-
omized  to  receive  geﬁtinib  250  or  500  mg/day.
fﬁcacy results  were  similar  between  the  dosing
roups;  the  ORR  was  12%  and  the  1-year  survival
ate was  25%.  In  both  studies,  grade  3—4  adverse
vents (AEs)  such  as  acne  form  rash  and  diarrhea
ere more  frequent  with  the  higher  dose  [31].
Based on  the  results  of  IDEAL  2,  geﬁtinib  received
ccelerated FDA  approval  as  a  third-line  therapy
or NSCLC.  However,  the  500-mg  geﬁtinib  dose  was
ore toxic  as  it  induced  more  acne-like  rash  and
iarrhea.  Diarrhea  was  noted  in  57%  of  patients
eceiving 250  mg  and  75%  in  those  receiving  500  mg.
kin toxicity  (rash,  acne,  dry  skin,  pruritus)  was
bserved  in  62%  and  75%,  respectively.  Grade  3/4
oxicities  were  unusual,  but  more  frequent  in  the
00-mg dosing.  Dose  reductions  as  a result  of  tox-
city were  also  more  frequent  in  the  higher  dose
32].
The subsequent  phase  3  ISEL  (Iressa  Survival
valuation in  Lung  cancer)  trial  found  that  geﬁtinib
id not  offer  a  signiﬁcant  OS  beneﬁt  compared  with
lacebo (5.6  vs  5.1  months,  respectively;  p  =  .087),
hich led  to  withdrawal  of  its  FDA  approval  [33].
The  reasons  of  lack  of  efﬁcacy  are  not  clear
ut it  can  be  related  to  the  use  of  lower  dose
hat are  less  than  the  maximum  tolerated  dose  and
he inclusion  of  primary  refractory  cancers.  Pre-
lanned  subgroup  analysis  of  data  from  ISEL  did  ﬁnd
mproved OS  with  geﬁtinib  versus  placebo  in  never-
mokers  (median  survival,  8.9  vs  6.1  months;  hazard
atio [HR]:  0.67,  p  =  .012)  and  in  patients  of Asian
rigin (median  survival,  9.5  vs  5.5  months;  HR:
.66, p  =  .01).  A  later  exploratory  biomarker  analy-
is found  a numeric  (but  not  statistically  signiﬁcant)
R beneﬁt  with  geﬁtinib  in  patients  with  EGFR
rotein-expressing  tumors  as  well  as  those  with
igh EGFR  copy  numbers.  Patients  whose  tumors
xpressed  EGFR  protein  also  had  a  numerically
reater survival  beneﬁt  (HR:  0.77;  p =  .126)  com-
ared with  those  whose  tumors  did  not  express
GFR (HR:  1.57;  p =  0.14).  The  presence  of  somatic
utations  in  EGFR  Exons  19  and  21  also  appeared
o predict  response  (RR,  37.5%  vs  2.6%;  p-value  not
eported) [34].
Another  phase  3  trial  evaluating  geﬁtinib  in
ung cancer  called  INTEREST  (Iressa  Non-small-cell
ung cancer  Trial  Evaluating  REsponse  and  Survival
gainst  Taxotere),  conducted  in  1466  patients  with
SCLC who  had  received  1  or  2 prior  chemother-
py regimens,  found  geﬁtinib  to  be  non  inferior
or survival  (median  OS  of  7.6  months;  1-year
urvival of  32%)  compared  with  docetaxel,  and
ffered  improved  tolerability  and  patient  quality
f life.  Preplanned  subgroup  analyses  found  one
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igniﬁcant  difference  between  the  treatment
roups: patients  who  had  received  2  prior
hemotherapy  regimens  had  better  survival  with
ocetaxel  than  with  geﬁtinib  (p  =  .031).  Overall,
mong patients  taking  geﬁtinib,  2.2%  had  grade
/4 hematologic  AEs,  whereas  docetaxel-treated
atients  had  a  58.2%  incidence  of  grade  3/4  neu-
ropenia  and  a  42.3%  incidence  of  grade  3/4
eukopenia [35].
rlotinib
rlotinib  has  shown  a  signiﬁcant  improvement  in
edian survival,  quality  of  life,  and  related  symp-
oms in  an  unselected  population  of  advanced  and
etastatic  NSCLC  patients  in  the  second  or  third-
ine setting  and  most  recently  in  maintenance
herapy.
National Cancer  Institute  of  Canada  Clinical  Tri-
ls Group  conducted  a  phase  III  randomized  trial,
amed  BR.21,  in  which  erlotinib  was  compared  with
lacebo in  stage  III/IV  NSCLC  patients  who  had
ailed  ﬁrst-  or  second-line  chemotherapy.
A total  of  731  patients  were  randomized  in  a
:1 ratio  to  receive  either  erlotinib  at  150  mg/day
r placebo.  Those  patients  had  metastatic  NSCLC
hat had  previously  been  treated  with  one
tandard chemotherapy  regimen  (50%  of  patients)
r with  two  chemotherapy  regimens  (50%  of
atients).  Almost  all  patients  received  platinum-
ased chemotherapy.  The  OR  rate  was  8.9%  in  the
rlotinib  arm  and  1%  in  the  placebo  group.  The
edian  durations  of  response  were  7.9  months  and
.7 months,  respectively.  The  median  over-all  sur-
ival time  was  6.7  months  for  those  in  the  erlotinib
egimen compared  with  4.7  months  for  those  in  the
lacebo arm.
ORs were  more  frequent  in  women  (14%  vs  6%),
n patients  with  adenocarcinoma,  as  compared  with
ther histotypes  (14%  vs  4.1%),  and  in  patients  with-
ut a  smoking  history  (25%  vs  4%)  [36].
The  global  TRUST  study  of  erlotinib  in  advanced
on-small-cell  lung  cancer  (NSCLC)  phase  4  trial
as conducted  in  over  7000  patients  with  advanced
SCLC  to  evaluate  erlotinib  in  the  second-  or  third-
ine setting.  The  study  revealed  that  patients  with
 broad  range  of  clinical  characteristics  including
ender, ethnicity,  smoking  status,  and  tumor  his-
ology beneﬁted  from  treatment  with  erlotinib  in
his setting.  Patients  had  a  PFS  of  14.3  weeks,  and
hile this  study  did  not  have  a  control  arm,  the  PFS
een with  erlotinib  in  the  TRUST  trial  was  almost
wice  that  observed  in  the  placebo  arm  of  BR.21
7.2  weeks).  Patients  in  the  TRUST  study  had  an
verall disease  control  rate  of  70%  at  the  time  of
nalysis  [37].
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In  the  TITAN  trial,  424  patients  who  progressed
n an  initial  platinum-based  chemotherapy  were
andomly  assigned  to  erlotinib  or  chemotherapy
ith either  docetaxel  or  pemetrexed  at  the  inves-
igator’s  discretion.  There  was  no  difference  in  OS
median 5.3  months  with  erlotinib  vs  5.5  months
ith chemotherapy,  HR  0.96)  or  PFS  (median  6.3
eeks with  erlotinib  vs  8.6  weeks  with  chemother-
py) between  both  arms  [38].
aintenance therapy
rlotinib
he  SATURN  (Sequential  Tarceva  in  Unresectable
ung Cancer)  phase  3  clinical  trial  is  evaluated
hether erlotinib  is  effective  as  maintenance  ther-
py in  advanced  NSCLC.
In this  multicenter,  double-blind,  randomized
tudy, 850  patients  with  advanced  (stage  IIIB/IV)
SCLC  were  randomized  to  receive  either  erlotinib
150 mg/day)  or  placebo,  after  documented  dis-
ase control  (CR/PR/SD),  after  4  cycles  of  standard
latinum-based  chemotherapy.
Treatment  is  continued  until  disease  progres-
ion, unacceptable  toxicity,  or  death.  The  primary
ndpoint  of  SATURN  is  to  determine  whether  admin-
stration  of  maintenance  erlotinib  after  standard
latinum-based is  beneﬁcial.  PFS  was  better  with
rlotinib versus  placebo  with  HR  0.71,  and  over-
ll survival  HR  was  0.81  [39].  The  improvement  in
FS was  greater  in  patient  with  EGFR  mutation  (HR
.009).
FAST-ACT:  A  phase  II randomized  double-blind
rial of  sequential  erlotinib  and  chemotherapy  as
rst-line treatment  in  patients  with  stage  IIIB/IV
on-small  cell  lung  cancer  (NSCLC),  a  placebo-
ontrol randomized  phase  2  study  of  150  unselected
atients from  Asia  and  Australia  using  gemcitabine
nd carboplatin  on  day  1  and  day  8  subsequently
ollowed by  erlotinib  from  days  15  to  28.  All
atients received  erlotinib  or  placebo  as  main-
enance therapy.  Tumor  RR  was  37%  versus  24%
n favor  of  the  sequential  erlotinib  study  arm.
edian progression-free  survival  was  7.2  months
ith erlotinib  versus  5.5  months  with  placebo  [40].
nother international  double-  blind  randomized
rial (called  ATLAS)  found  a beneﬁt  from  combin-
ng 2  targeted  maintenance  therapies  after  initial
reatment  in  patients  with  advanced  non-small  cell
ung cancer.  The  trial  revealed  that  combination
herapy with  erlotinib  and  bevacizumab  is  supe-
ior to  bevacizumab  alone  for  delaying  disease
rogression.
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A  total  of  768  patients  were  randomized  to
receive bevacizumab  plus  erlotinib  or  bevacizumab
plus placebo,  after  initial  treatment  with  beva-
cizumab.  In  patients  treated  with  both  drugs,
investigators noted  a  median  progression-free  sur-
vival of  4.8  months,  compared  with  3.7  months
in those  receiving  bevacizumab  plus  placebo.  The
progression-free  survival  rate  at  3  months  was
67.7%  in  the  combination  group  versus  53.4%  in
the control  group;  at  6 months,  the  rates  were
40.3% and  28.4%,  respectively.  Because  of  these
results,  which  were  from  a  planned  interim  anal-
ysis of  the  data,  the  ATLAS  trial  was  stopped  early
[41].
Geﬁtinib
A  randomized  phase  3  trial  conducted  by  the  West
Japan Thoracic  Oncology  Group  evaluated  the  geﬁt-
inib maintenance  therapy  after  platinum-doublet
chemotherapy  in  previously  untreated  patients
with advanced  disease.  Eligible  patients  were  ran-
domized to  receive  either  3  cycles  of  chemotherapy
followed by  geﬁtinib  maintenance  therapy  or  6
cycles of  chemotherapy.  Geﬁtinib  maintenance
therapy was  associated  with  a  signiﬁcant  improve-
ment in  progression-free  survival  duration  (HR,
0.68; 95%  CI:  0.57—0.80;  p  <  .001)  but  not  in  OS.
A pre  speciﬁed  analysis  of  OS  by  subgroup  showed  a
signiﬁcant improvement  in  OS  with  geﬁtinib  main-
tenance  in  patients  with  adenocarcinoma  histology
[42].
Cetuximab
Cetuximab  when  administered  in  combination  with
carboplatin  and  docetaxel,  a  commonly  used  regi-
men for  advanced  NSCLC,  cetuximab  has  exhibited
synergistic  interaction  in  preclinical  studies.  There-
fore, a  phase  2  study  was  conducted  to  evaluate
the efﬁcacy  of  the  combination  of  cetuximab,
carboplatin,  and  docetaxel  for  the  treatment  of
advanced  NSCLC.
80  patients  chemotherapy-naıve  with  stage  IIIB
or stage  IV  NSCLC  received  cetuximab  (at  a dose
of 400  mg/m2 on  day  1  and  250  mg/m2 on  days  8
and 15)  plus  docetaxel  (at  a  dose  of  75  mg/m2 on
day 1)  and  carboplatin  (area  under  the  concentra-
tion vs  time  curve  [AUC]  5—6  on  day  1)  every  21
days for  up  to  6  cycles.  Thereafter,  patients  with-
out evidence  of  disease  progression  were  continued
on single-agent  cetuximab  for  a  maximum  of  1  year
or until  disease  progression.  In  5  (28%)  patients,  dis-
ease stabilization  lasted  for  >6  months.  The  median
progression-free  survival  was  4.6  months  and  4
t
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atients  (14%)  remained  free  of  disease  progression
t 12  months.  The  median  survival  and  1-year  sur-
ival rate  were  10.3  months  and  36%,  respectively.
he 2-year  survival  rate  was  16%  [43].
Resistance  to  EGFR  TK  inhibitors:
Almost all  patients  who  initially  respond  to  an
EGFR TK  inhibitor  subsequently  develop  dis-
ease progression.  The  two  molecular  mechanisms
that are  responsible  for  a majority  of  cases  of
acquired  resistance  are  secondary  mutation  at
EGFR (T790)  or  ampliﬁcation  of  MET  oncogen.
There is  ongoing  clinical  trials  for  agents  with
in vitro  activity  against  T790M  or  MET  for  patient
with  NSCLC  [44,45].
ew tyrosine kinase inhibitor exhibits
linical  activity for non-small cell lung
ancer with ALK oncogene fusions
 new  inhibitor  of  the  ALK  and  c-MET/hepatocyte
rowth  factor  (HGF)  receptor  tyrosine  kinases,
rizotinib (PF-02341066),  has  produced  an  objec-
ive response  rate  (ORR)  of  57%,  disease  control
ate (DCR)  of  87%,  and  progression-free  survival
PFS) probability  at  6  months  of  72%,  with  an
xcellent safety  proﬁle,  in  patients  with  non-small
ell lung  cancer  (NSCLC).  82  patients  have  been
reated.  Almost  all  patients  had  adenocarcinoma
istology and  were  never  or  former  smokers.  Almost
ll patients  had  some  tumor  shrinkage.  The  median
uration  of  treatment  is  5.7  months.  The  ORR  is
7% (or  63%  pending  ﬁve  as  yet  unconﬁrmed  par-
ial responses)  and  the  DCR  is  87%.  The  ORR  for
atients with  three  or  more  previous  treatments  is
6%. Response  duration  varies  from  1 to  15  months.
edian  PFS  has  not  been  reached.  Toxicity  has
een observed,  elevated  alanine  aminotransferase
ALT), lymphopenia,  hypophosphatemia,  neutrope-
ia, hypoxia,  dyspnea,  and  pulmonary  embolism,
otaling an  overall  rate  of  12%  [46].  Crizotinib  was
ecently  approved  by  the  US  FDA  for  the  treatment
f NSCLC  with  Alk  fusion.
ombined irreversible inhibition of EGFR
fatinib  (BIBW2992)  is a novel  PanErb  inhibitor.  It
rreversibly inhibits  EGFR,  HER-2  and  HER-4.
In 2012  ASCO  Meeting,  LUX-Lung  3  study  was
resented revealing  signiﬁcant  improvement  in  pro-
ression free  survival  of  patients  with  advanced
denocarcinoma  harboring  EGFR  mutation  with  Afa-
inib in  comparison  to  cisplatin-pemetrexed  [47].
In this  phase  III  randomized  study  that  included
45 patients,  PFS  was  11.1  months  versus  6.9
onths  (HR:  0.47  (0.34—065),  p  <  0.0001)  in  favor
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f  Afatinib.  Objective  response  rate  was  more  than
oubled with  Afatinib  (56%  vs  23%;  p  <  0.0001).
These data  reﬂect  the  efﬁcacy  of  Afatinib  in
his setting  but  awaiting  further  details  to  incorpo-
ate this  into  practice  including  regulatory  agencies
ecisions  about  the  drug  approval.
ide effects and management
hese  new  agents  are  associated  with  unique  side
ffects especially  in  term  of  skin  and  gastrointesti-
al toxicities.  It  is  very  prudent  for  initiate  early
reatment  of  these  toxicities  to  avoid  interruption
f treatment  or  severe  complications.
espiratory side effects
espiratory  side  effects  have  included  reports  of
erious interstitial  lung  disease  (ILD);  including
atalities in  the  treatment  of  non-small  cell  lung
ancer or  other  advanced  solid  tumors.  Dyspnea
41%) and  cough  (33%)  have  also  been  reported.  In
ases of  ILD,  the  medication  should  be  discontinued
mmediately and  trial  of  steroid  or  cyclophos-
hamide was  reported  but  no  conclusive  beneﬁt
48].
ermatologic side effects
ermatologic  side  effects  are  common  and  include
ash (75%),  pruritus  (13%),  dry  skin  (12%),  alope-
ia, acneform  rash  and  other  dermatological  ﬁnding
The median  time  to  onset  of  rash  was  8 days.
reatment should  be  interrupted  or  discontinued
f the  patient  develops  severe  bullous,  blistering,
r exfoliating  conditions.  The  appearance  of  a  rash
n cancer  patients  treated  with  EGFR  inhibitors  is
trongly associated  with  better  outcome.  Patients
ith  mild  skin  changes  may  not  need  any  treatment.
atients  who  are  symptomatic  should  be  treated
ccordingly.  Emollients  can  be  administered  for  skin
ryness. Moderate  skin  rash  can  be  treated  with
opical  antibiotics  such  as  clindamycin  gel  or  topi-
al metronidazole,  a  short  course  of  oral  antibiotics
uch as  minocycline  or  doxycycline  may  be  com-
ined  with  the  topical  therapy.  Patients  who  fail  to
espond to  these  measures  may  have  the  dose  of
he EGFR  inhibitor  interrupted  or  dose  reduced.
astrointestinal side effects
astrointestinal  side  effects  including  diarrhea
54%), nausea  (33%),  vomiting  (23%),  stomati-
is (17%),  and  abdominal  pain  (11%)  have  been
eported. EGFR  is  frequently  overexpressed
n gastrointestinal  normal  mucosa.  There  is
F cancer  management  S57
vidence  that  EGFR  is  a  negative  regulator  of
hloride  secretion.  EGFR  inhibitors  could,  there-
ore, increase  chloride  secretion  by  blocking  this
egulation  loop  and  thereby  inducing  secretory
iarrhea.
Diarrhea induced  by  inhibitors  that  target  the
GFR pathway  can  be  managed  easily  by  reducing
he dose  of  the  oral  compound,  which  rapidly  low-
rs the  incidence  and  severity  of  diarrhea.  Rarely
oes treatment  have  to  be  interrupted.  Loperamide
s a useful  treatment  that  can  decrease  intestinal
otility [49].
ther toxicities
ike  ocular  complication  such  as  conjunctivitis,
epatic as  increase  in  Liver  Function  Tests,  renal,
ematologic  side  effects  including  leukopenia  (25%)
nd anemia  (16%)  have  been  reported  in  patients
eceiving cetuximab.
onclusion
emarkable  developments  in  the  systemic  treat-
ent of  advanced  non-small-cell  lung  cancer
ave taken  place  over  the  past  few  years.  Tar-
eted therapies  have  been  largely  employed  in
atients with  far  advanced  disease,  and  some  of
hem have  demonstrated  consistent  activity  in
his setting.  Epidermal  growth  factor  receptor
nhibitors cause  dramatic  response  in  patients
specially with  EGFR  mutation.  As  oncology  trends
owards  personalized  therapy  to  reach  the  opti-
al efﬁcacy  of  drug  with  less  side  effect,  anti
GFR and  or  third  line  TKIs  have  proven  to  be
romising effective  drugs  in  lung  cancer  treat-
ent as  ﬁrst,  second  and  maintenance  therapy
hich encouraging  further  trials  in  this  ﬁeld.
ombined irreversible  inhibition  of  EGFR  revealed
triking  beneﬁt  compared  to  chemotherapy
lone.
The development  of  resistance,  tumor  hetero-
eneity, and  the  need  to  rebiopsy  the  tumor  are  all
hallenges  that  requires  further  study  to  optimize
he management  of  patients  with  NSCLC.
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